Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
|ClinicalTrials.gov Identifier: NCT00003562|
Recruitment Status : Unknown
Verified March 2001 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : May 21, 2004
Last Update Posted : December 4, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Drug: carboplatin Drug: docetaxel||Phase 2|
OBJECTIVES: I. Determine the effectiveness of low dose docetaxel and carboplatin by response rate, response duration, and time to progression in patients with stage IIIB or IV non-small cell lung cancer. II. Determine the side effects and toxicity profile of docetaxel when given in combination with carboplatin in these patients.
OUTLINE: This is open label study. Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 30 minutes once a week for 4 weeks. Patients receive at least 2 courses (8 weeks) of treatment. Courses are further repeated in the absence of unacceptable toxicity and disease progression.
PROJECTED ACCRUAL: There will be 20-38 patients accrued into this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||38 participants|
|Official Title:||A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin|
|Study Start Date :||July 1998|
U.S. FDA Resources
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003562
|United States, Kansas|
|Bethany Medical Center|
|Kansas City, Kansas, United States, 66102|
|Heartland Cancer Research Network|
|Kansas City, Kansas, United States, 66106|
|Study Chair:||Raj Sadasivan, MD, PhD||Hope Cancer Institute, Inc.|